2015 Second Quarter Earnings Call

July 30, 2015

Forward-Looking Statements

2

Some of the statements made in this presentation whether written or

oral may be “forward-looking statements” within the meaning of Section

27A of the Securities Act of 1933, as amended, and Section 21E of the

Securities Exchange Act of 1934, as amended, and involve a number of

risks and uncertainties. These statements can be identified by

terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,”

“plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential”, or

“continue”, or “variations” or the negative of these terms or other

comparable terminology.

These statements are based on the company’s current expectations.

The company’s actual results could differ materially from those stated or

implied in such forward-looking statements. The company assumes no

obligations to update forward-looking information, including information

in this presentation, to reflect changed assumptions, the occurrence of

unanticipated events or changes in future operating results, financial

conditions, prospects or otherwise.

Earnings Call Participants

Thomas J. Hook

President & CEO

Michael Dinkins

Executive Vice President & CFO

Betsy Cowell

Vice President Finance & Treasurer

3

Agenda

Thomas J. Hook

Executive Summary

Second Quarter 2015 Performance

Nuvectra Update

Michael Dinkins

Balance Sheet Review

2015 Guidance Update

Question & Answer

4

Executive Summary

We are confirming 2015 guidance

We delivered solid growth in the Cardiac/Neuro,

Orthopaedics, and Portable Medical product lines resulting

in an overall 4% constant currency organic growth

Our operating margin declined 90 bps this quarter primarily

because of product mix

We filed the Form 10 registration statement with the SEC for

our proposed spin-off, Nuvectra

5

Selected Q2 2015 Highlights

6 * Greatbatch organic constant currency growth rate: 4%; Orthopaedics organic constant currency growth rate:8% ** See appendix for GAAP reconciliation except for ROIC (TTM) 6

Adj. EPS Comments

2014 Q2 Adjusted EPS $ 0.61

Volume/Price (0.01) Neuromodulation growth offset by lower volume in

our core products and price

Operating expenses (0.04) Increased OpEx driven by CCC Medical Devices

acquisition and timing of RDE spending

Taxes 0.08 Tax rate

2015 Q2 Adjusted EPS $0.64

Three Months Ended

(Dollars in thousands, except per share

data)

July 3, July 4, %

2015 2014 Change

Sales $ 174,890

$ 172,081

2 %

Organic Constant Currency Sales Growth 4 % — %

Adjusted Operating Income* $ 22,243

$ 24,188

(8 )%

Adjusted Operating Income as % of Sales 12.7 % 14.1 %

Adjusted Diluted EPS* $ 0.64

$ 0.61

5 %

Adjusted EBITDA* $ 31,259

$ 33,497

(7 )%

Adjusted EBITDA as a % Sales 17.9 % 19.5 %

Q2 2015 Revenue

7

*Intersegment sales between Greatbatch Medical and QiG are eliminated in consolidation and are included in Greatbatch Medical’s cardiac and

neuromodulation product line.

Q2 2015 Q2 2014 % Organic

Actual Actual Change CC Growth

Greatbatch Medical

CN $90,153 $80,005 12.7% 12.7%

Orthopaedics 35,481 37,865 -6.3% 8.2%

Portable Medical 17,700 16,737 5.8% 5.8%

Vascular 12,907 15,257 -15.4% -15.4%

Energy & Other 16,545 21,352 -22.5% -22.5%

Total Greatbatch Medical 172,786 171,216 0.9% 4.1%

QiG 2,741 865 216.9% 73.2%

Elimination of Intersegment Sales* -637 NA

Total Sales $174,890 $172,081 1.6% 4.1%

Cardiac/Neuromodulation

Battery

Feedthrough

Enclosure

Q2 revenue up 18% on a sequential quarter basis … YTD in line

with expectations

Strong Neuromodulation growth

Batteries and shield assemblies continue to deliver strong growth

Coated

Electrode

Q2 YTD R4Q

Revenue $89,516* $165,085* $319,719

% of Total

Revenue

52%* 50%* 48%

Growth 12%* -1%* -6%

8

Greatbatch Sustainable Advantages

Strong and expanding customer relationships

90% of the portfolio secured by long term agreements

Sustainable and growing patent portfolio

Innovative product offerings (+20 programs)

*Net of intersegment sales ;reported CN Sales total $90,153 for Q2 and $166,426 for YTD

Orthopaedics

Implant and instruments growing double digits

Reamer

Delivery System

Implant

9

Greatbatch Sustainable Advantages

Strong and expanding customer relationships

70% secured by long term agreements

Continued strong market acceptance in bone cutting and

preparation technologies

Q2 YTD R4Q

Revenue $35,481 $74,452 $147,452

% of Total Revenue 21% 23% 22%

Organic CC Growth 8% 13% 11%

Portable Medical

Integrated Power

Supplies

Battery Packs

Amounts in millions

Executing the shift to higher value technologies

Building pipeline with new power solutions technology

Leveraging our global footprint to improve overall competitiveness

10

Greatbatch Sustainable Advantages

Focus on innovative proprietary powers solutions

Wireless charging and power

Miniaturization … Batteries and power cells

Value added assembly capabilities

Securing portfolio through LTAs with largest customers

New Product Introductions – 20 active projects

Q2 YTD R4Q

Revenue $17,700 $31,367 $64,470

% of Total

Revenue

10% 10% 10%

Growth 6% -13% -12%

Vascular

Customer inventory management programs easing

New product introductions in the 2nd half will mitigate EOL headwind

On track with product transitions to Mexico

Focus on high growth sectors Complex, steerable catheter shafts for Electrophysiology market

Catheter shafts for peripheral and neuro vascular markets

Introducer

Steerable Sheath

Amounts in millions

Amounts in millions

11

Greatbatch Sustainable Advantages

Expanding customer relationships with 50% secured by long-

term agreements

Specialized manufacturing know-how

Leveraging global manufacturing foot print

Innovative product offerings

Q2 YTD R4Q

Revenue $12,907 $23,263 $53,726

% of Total

Revenue

7% 7% 8%

Growth -15% -18% 0%

EME

Amounts in millions

Weak demand in Energy market

Wide range and high temperature battery technologies enhances

the customers exploration and production activity efficiencies

12

Greatbatch Sustainable Advantages

Industry leading quality and reliability … 40+ years

experience with critical applications Extensive battery chemistry knowledge/fundamentals

including proprietary electrolytes

Developing technologies, such as monitoring, to provide

product offerings that enhance our customers’ capabilities

Ability to leverage a diversified, enterprise wide, knowledge

base

State-of-the-art production facilities

Battery Packs

Battery Cells

Battery Chargers

Q2 YTD R4Q

Revenue $16,545 $34,255 $76,529

% of Total

Revenue

10% 10% 12%

Growth -23% -13% -3%

Nuvectra Update

13

Our platform has the capability to provide treatment to patients

in several established Neurostimulation markets such as SCS,

SNS, DBS and other emerging Neurostimulation markets

Our Algovita SCS system is the first application of our

Neurostimulation technology platform

FDA approval process continues and we expect second half

approval

We expect the spinoff to occur prior to the end of 2015

Nuvectra Update

14

We filed the Form 10 on July 30, 2015

15

Dividend of Nuvectra shares to our Greatbatch shareholders

Reduced operating expenses of $12 to $16 million annually

Long term manufacturing agreement with Nuvectra

Nuvectra Spin-off Will Benefit Our Shareholders Three

Different Ways:

Balance Sheet & ROIC

16

Balance Sheet Metrics

($ in millions except for EPS)

17

Q2 2015 Q2 2014 FY2014

Days Sales Outstanding 65 65 66

Days Inventory Outstanding 112 94 103

Leverage Ratio <1.5 <1.5 <1.5

Our balance sheet is solid, inventory is in place to

support second half revenue and our capital

structure continues to be below 1.5

Trailing 12 months Q2 2015 Q2 2014

Adjusted EBITDA $123.8 $125.0

ROIC 7.8% 8.2%

YTD Q2 2015 Q2 2014

Working Capital $256.8 $232.6

Operating Cash Flow $22.5 $26.5

CapEx $22.2 $12.0

2015 Guidance

18

2015 Guidance – Confirming Guidance

19

(In millions, except for EPS amounts)

2014

2015 Guidance

Sales $687.8 $715 - $730

Adjusted Operating Margin 13.3% 13.7% - 14.0%

Adjusted Diluted EPS $2.42 $2.61 - $2.71

Operating Cash Flows $81.3 $80 - $100

Capex $24.8 $40 - $50

ROIC 8.4% 9.0%

Annualized Adjusted

EBITDA* EPS

Value of Nuvectra shares TBD TBD

Reduced Operating Expenses $12M - $16M $0.29 to $0.39

Incremental revenue from

manufacturing contract with Nuvectra TBD TBD

Nuvectra Spin-off Will Enhance Our Financial Performance

20

* Timing of FDA approval will impact the 2015/2016 calendar year results

Management Focused On Delivering Shareholder Value

21

Strategic Initiatives

Organic Growth Medical Device Systems

Margin Expansion Targeted Acquisitions

Market

Cap

2014A

P/E

2015E

P/E

2014A

EV/EBITDA

2015E

EV/EBITDA

2014A

EV/Sales

2015E

EV/Sales

$1,375 22.3 19.2 11.6 10.9 2.2 2.1

-10%0%

10%20%30%40%50%60%70%80%90%

100%110%120%130%140%150%

7/2/2012 7/2/2013 7/2/2014 7/2/2015

GB

S&P 500

Dow Jones

NYSE

NASDAQ

Russell 2000

($MM)

Appendix

22

Selected 1ST Half 2015 Highlights

23 * Greatbatch organic constant currency growth rate: -2%; Orthopaedics organic constant currency growth rate:13% ** See appendix for GAAP reconciliation except for ROIC (TTM) 23

Adj. EPS Comments

2014 YTD Adjusted EPS $ 1.16

Volume/Price (0.15) Lower volumes partially offset neuromodulation growth

and favorable performance based compensation

Operating expenses (0.02)

Higher operating expenses attributable to CCC Medical

Devices acquisition and Algovita commercialization

partially offset by lower performance based

compensation and favorable RDE spending

Taxes/Other 0.20 Tax rate and favorable FX gains partially offset by

higher share count

2015 YTD Adjusted EPS $1.19

2015 2014

(Amounts in millions except for EPS) YTD YTD Variance

Sales* $336.2 $346.4 -3%

Adjusted:**

Operating Income $40.2 $46.7 -14%

EBITDA $58.4 $65.4 -11%

ROIC (TTM) 7.8% 8.2% -40 BPS

Operating Cash flow $22.5 $26.5 -15%

Diluted EPS $1.19 $1.16 3%

1st Half 2015 Revenue

24

*Intersegment sales between Greatbatch Medical and QiG are eliminated in consolidation and are included in Greatbatch Medical’s cardiac and

neuromodulation product line.

1H 2015 1H 2014 % Organic

Actual Actual Change CC Growth

Greatbatch Medical

CN $166,426 $166,785 -0.2% -0.2%

Orthopaedics 74,452 74,296 0.2% 13.0%

Portable Medical 31,367 35,940 -12.7% -12.7%

Vascular 23,263 28,307 -17.8% -17.8%

Energy & Other 34,255 39,483 -13.2% -13.2%

Total Greatbatch Medical 329,763 344,811 -4.4% -1.6%

QiG 7,788 1,551 402.1% 72.2%

Elimination of Intersegment Sales* -1,341 NA

Total Sales $336,210 $346,362 -2.9% -1.7%

Q2 2015 Financial Results

25

Three Months Ended

(Dollars in thousands, except per share data)

July 3, July 4, %

2015 2014 Change

Sales $ 174,890

$ 172,081

2 %

Organic Constant Currency Sales Growth 4 % — %

GAAP Operating Income $ 13,034

$ 19,539

(33 )%

GAAP Operating Income as % of Sales 7.5 % 11.4 %

Adjusted Operating Income* $ 22,243

$ 24,188

(8 )%

Adjusted Operating Income as % of Sales 12.7 % 14.1 %

GAAP Diluted EPS $ 0.35

$ 0.48

(27 )%

Adjusted Diluted EPS* $ 0.64

$ 0.61

5 %

Adjusted EBITDA* $ 31,259

$ 33,497

(7 )%

Adjusted EBITDA as a % Sales 17.9 % 19.5 %

1st Half 2015 Cash Flow

($ in millions)

26

Net income* $17.3

Adjustments to reconcile net income to net cash provided by (used in) operating activities:

Depreciation and Amortization 18.2

Debt related Amortization included on Int Expense 0.4

Stock Based Compensation/Discount Amortization 6.0

Other non-cash Gains 0.0

Deferred Income Taxes -1.9

Changes in operating assets and liabilities, net of acquisitions:

Accounts receivable 3.7

Inventories -10.9

Prepaid expenses and other current assets -1.3

Accounts payable -0.8

Accrued expenses -7.2

Income taxes payable -0.8

Net cash provided by operating activities $ 22.5

* GAAP net income

GAAP Reconciliation

Operating Income Reconciliation – 3 Months

27

Three Months Ended

Greatbatch Medical QiG Unallocated Total

July 3, July 4, July 3, July 4, July 3, July 4, July 3, July 4,

(dollars in thousands) 2015 2014 2015 2014 2015 2014 2015 2014

Sales $ 172,786 $ 171,216 $ 2,741 $ 865 $ (637 ) $ — $ 174,890 $ 172,081

Operating income (loss)

as reported $ 28,914

$ 32,439

$ (7,002 ) $ (6,173 ) $ (8,878 ) $ (6,727 ) $ 13,034

$ 19,539

Adjustments:

IP related litigation

(SG&A) —

—

—

—

1,459

388

1,459

388

Consolidation and

optimization (income)

expenses 6,532

3,342

37

38

—

(5 ) 6,569

3,375

Acquisition and

integration (income)

expenses 8

30

53

(173 ) 37

190

98

47

Asset dispositions,

severance and other 106

3

(3 ) —

980

836

1,083

839

Adjusted operating

income (loss) $ 35,560

$ 35,814

$ (6,915 ) $ (6,308 ) $ (6,402 ) $ (5,318 ) $ 22,243

$ 24,188

Adjusted operating

margin 20.6 % 20.9 % NA NA NA NA 12.7 % 14.1 %

GAAP Reconciliation

Operating Income Reconciliation – 6 Months

28

Six Months Ended

Greatbatch Medical QiG Unallocated Total

July 3, July 4, July 3, July 4, July 3, July 4, July 3, July 4,

(dollars in thousands) 2015 2014 2015 2014 2015 2014 2015 2014

Sales $ 329,763 $ 344,811 $ 7,788 $ 1,551 $ (1,341 ) $ — $ 336,210 $ 346,362

Operating income (loss)

as reported $ 50,667

$ 67,567

$ (12,452 ) $ (12,086 ) $ (15,792 ) $ (13,418 ) $ 22,423

$ 42,063

Adjustments:

IP related litigation

(SG&A) —

—

—

—

2,159

762

2,159

762

Consolidation and

optimization expenses 13,303

2,920

426

66

—

232

13,729

3,218

Acquisition and

integration (income)

expenses 8

30

97

(603 ) 59

192

164

(381 )

Asset dispositions,

severance and other 222

(7 ) (3 ) —

1,493

1,217

1,712

1,210

Adjusted operating

income (loss) $ 64,200

$ 70,510

$ (11,932 ) $ (12,623 ) $ (12,081 ) $ (11,015 ) $ 40,187

$ 46,872

Adjusted operating

margin 19.5 % 20.4 % NA NA NA NA 12.0 % 13.5 %

Net Income and Diluted EPS Reconciliation

GAAP Reconciliation

a) Net of tax amounts computed using a 35% U.S., Mexico, and France statutory tax rate, a 25% Uruguay statutory tax rate and a 0% tax rate for Swiss adjustments.

b) Pre-tax amount is a gain of $42 thousand and $540 thousand for the 2015 quarter and year-to-date periods, respectively, and a loss of $42 thousand and gain of

$780 thousand for the 2014 quarter and year-to-date periods, respectively.

a) The Federal R&D tax credit has not yet been extended for 2015. The 2014 Federal R&D tax credit was enacted in the fourth quarter of 2014. Amounts assume

that the tax credit was effective at the beginning of the year for 2015 and 2014.

b) The per share data in this table has been rounded to the nearest $0.01 and therefore may not sum to the total.

29

Three Months Ended Six Months Ended

July 3,

2015

July 4,

2014

July 3,

2015

July 4,

2014

(in thousands except per share amounts)

Net

Income

Per

Diluted

Share

Net

Income

Per

Diluted

Share

Net

Income

Per

Diluted

Share

Net

Income

Per

Diluted

Share

Net income as reported $ 9,283 $ 0.35 $ 12,348 $ 0.48 $ 17,291 $ 0.66 $ 27,270 $ 1.06

Adjustments:

IP related litigation (SG&A)(a) 948 0.04 252 0.01 1,403 0.05 495 0.02

Consolidation and optimization

expenses(a) 5,361

0.20

2,181

0.08

10,899

0.41

1,255

0.05

Acquisition and integration (income)

expenses(a) 70

—

31

—

116

—

(248 ) (0.01 )

Asset dispositions, severance and

other(a) 698

0.03

545

0.02

1,132

0.04

787

0.03

(Gain) loss on cost and equity

method investments, net(a)(b) (27 ) —

27

—

(351 ) (0.01 ) (507 ) (0.02 )

R&D Tax Credit(c) 400 0.02 400 0.02 800 0.03 800 0.03

Adjusted net income and diluted

EPS(d) $ 16,733

$ 0.64

$ 15,784

$ 0.61

$ 31,290

$ 1.19

$ 29,852

$ 1.16

Adjusted diluted weighted average

shares 26,313

25,901

26,264

25,823

Adjusted EBITDA reconciliation

GAAP Reconciliation

30

Three Months Ended Six Months Ended

July 3, July 4, July 3, July 4,

(dollars in thousands) 2015 2014 2015 2014

Sales $ 174,890

$ 172,081

$ 336,210

$ 346,362

Adjusted operating income* $ 22,243

$ 24,188

$ 40,187

$ 46,872

Add: Depreciation and amortization 9,016

9,309

18,194

18,561

Adjusted EBITDA $ 31,259

$ 33,497

$ 58,381

$ 65,433

Adjusted EBITDA as a % of sales 17.9 % 19.5 % 17.4 % 18.9 %

Betsy Cowell Vice President Finance & Treasurer Greatbatch 2595 Dallas Parkway Suite 310 Frisco, Texas 75034 214 618 4982 ecowell@greatbatch.com www.greatbatch.com

Contact Information

31